| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| VRTX - Vertex Pharmaceuticals Inc | BUY | 712 @ USD 455.71 | USD 324,466 | The ETF bought 712 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 455.71 compared to the previous average buy price of 440.112. This is 3.5% higher than average price of previous purchases of VRTX. |
| AMGN - Amgen Inc | BUY | 966 @ USD 325.31 | USD 314,249 | The ETF bought 966 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 325.31 compared to the previous average buy price of 303.059. This is 7.3% higher than average price of previous purchases of AMGN. |
| GILD - Guild Esports Plc | BUY | 2,462 @ USD 119.78 | USD 294,898 | The ETF bought 2462 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 119.78 compared to the previous average buy price of 116.174. This is 3.1% higher than average price of previous purchases of GILD. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 348 @ USD 752.62 | USD 261,912 | The ETF bought 348 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 752.62 compared to the previous average buy price of 650.852. This is 15.6% higher than average price of previous purchases of REGN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 436 @ USD 391.5 | USD 170,694 | The ETF bought 436 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 391.5 compared to the previous average buy price of 387.833. This is 0.9% higher than average price of previous purchases of ALNY. |
| AZN - AstraZeneca PLC | BUY | 1,740 @ USD 91.56 | USD 159,314 | The ETF bought 1740 new shares of AZN (AstraZeneca PLC). The shares were bought for an average price of 91.56 compared to the previous average buy price of 78.7748. This is 16.2% higher than average price of previous purchases of AZN. |
| INSM - Insmed Inc | BUY | 710 @ USD 196.92 | USD 139,813 | The ETF bought 710 new shares of INSM (Insmed Inc). The shares were bought for an average price of 196.92 compared to the previous average buy price of 142.214. This is 38.5% higher than average price of previous purchases of INSM. |
| ARGX - argenx NV ADR | BUY | 102 @ USD 850.95 | USD 86,797 | The ETF bought 102 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 850.95 compared to the previous average buy price of 718.636. This is 18.4% higher than average price of previous purchases of ARGX. |
| BIIB - Biogen Inc | BUY | 492 @ USD 175.74 | USD 86,464 | The ETF bought 492 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 175.74 compared to the previous average buy price of 149.552. This is 17.5% higher than average price of previous purchases of BIIB. |
| UTHR - United Therapeutics Corporation | BUY | 152 @ USD 500.3 | USD 76,046 | The ETF bought 152 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 500.3 compared to the previous average buy price of 382.166. This is 30.9% higher than average price of previous purchases of UTHR. |
| ILMN - Illumina Inc | BUY | 516 @ USD 134.92 | USD 69,619 | The ETF bought 516 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 134.92 compared to the previous average buy price of 105.586. This is 27.8% higher than average price of previous purchases of ILMN. |
| INCY - Incyte Corporation | BUY | 656 @ USD 98.64 | USD 64,708 | The ETF bought 656 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 98.64 compared to the previous average buy price of 81.564. This is 20.9% higher than average price of previous purchases of INCY. |
| RPRX - Royalty Pharma Plc | BUY | 1,454 @ USD 38.53 | USD 56,023 | The ETF bought 1454 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 38.53 compared to the previous average buy price of 36.6926. This is 5.0% higher than average price of previous purchases of RPRX. |
| MEDP - Medpace Holdings Inc | BUY | 94 @ USD 559.13 | USD 52,558 | The ETF bought 94 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 559.13 compared to the previous average buy price of 445.051. This is 25.6% higher than average price of previous purchases of MEDP. |
| NBIX - Neurocrine Biosciences Inc | BUY | 334 @ USD 154.06 | USD 51,456 | The ETF bought 334 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 154.06 compared to the previous average buy price of 135.59. This is 13.6% higher than average price of previous purchases of NBIX. |
| ROIV - Roivant Sciences Ltd | BUY | 2,290 @ USD 21.9 | USD 50,151 | The ETF bought 2290 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 21.9 compared to the previous average buy price of 15.2585. This is 43.5% higher than average price of previous purchases of ROIV. |
| RVMD - Revolution Medicines Inc | BUY | 630 @ USD 79 | USD 49,770 | The ETF bought 630 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 79 compared to the previous average buy price of 50.2004. This is 57.4% higher than average price of previous purchases of RVMD. |
| BBIO - BridgeBio Pharma Inc | BUY | 644 @ USD 74.51 | USD 47,984 | The ETF bought 644 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 74.51 compared to the previous average buy price of 52.1489. This is 42.9% higher than average price of previous purchases of BBIO. |
| VTRS - Viatris Inc | BUY | 3,912 @ USD 11.66 | USD 45,614 | The ETF bought 3912 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 11.66 compared to the previous average buy price of 9.92212. This is 17.5% higher than average price of previous purchases of VTRS. |
| ASND - Ascendis Pharma AS | BUY | 204 @ USD 213.24 | USD 43,501 | The ETF bought 204 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 213.24 compared to the previous average buy price of 186.492. This is 14.3% higher than average price of previous purchases of ASND. |
| SMMT - Summit Therapeutics PLC | BUY | 2,500 @ USD 17.38 | USD 43,450 | The ETF bought 2500 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 17.38 compared to the previous average buy price of 20.335. This is -14.5% lower than average price of previous purchases of SMMT. |
| SNY - Sanofi ADR | BUY | 904 @ USD 47.82 | USD 43,229 | The ETF bought 904 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 47.82 compared to the previous average buy price of 49.9057. This is -4.2% lower than average price of previous purchases of SNY. |
| GH - Guardant Health Inc | BUY | 418 @ USD 102.67 | USD 42,916 | The ETF bought 418 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 102.67 compared to the previous average buy price of 68.7623. This is 49.3% higher than average price of previous purchases of GH. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 534 @ USD 79.76 | USD 42,592 | The ETF bought 534 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 79.76 compared to the previous average buy price of 56.9603. This is 40.0% higher than average price of previous purchases of IONS. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 74 @ USD 560.55 | USD 41,481 | The ETF bought 74 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 560.55 compared to the previous average buy price of 412.669. This is 35.8% higher than average price of previous purchases of MDGL. |
| MRNA - Moderna Inc | BUY | 1,310 @ USD 29.92 | USD 39,195 | The ETF bought 1310 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 29.92 compared to the previous average buy price of 27.991. This is 6.9% higher than average price of previous purchases of MRNA. |
| EXEL - Exelixis Inc | BUY | 906 @ USD 41.38 | USD 37,490 | The ETF bought 906 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 41.38 compared to the previous average buy price of 41.7216. This is -0.8% lower than average price of previous purchases of EXEL. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 204 @ USD 169.53 | USD 34,584 | The ETF bought 204 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 169.53 compared to the previous average buy price of 135.587. This is 25.0% higher than average price of previous purchases of JAZZ. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 646 @ USD 52.12 | USD 33,670 | The ETF bought 646 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 52.12 compared to the previous average buy price of 57.0707. This is -8.7% lower than average price of previous purchases of BMRN. |
| BNTX - BioNTech SE | BUY | 340 @ USD 93.81 | USD 31,895 | The ETF bought 340 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 93.81 compared to the previous average buy price of 102.957. This is -8.9% lower than average price of previous purchases of BNTX. |
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 464 @ USD 68.45 | USD 31,761 | The ETF bought 464 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 68.45 compared to the previous average buy price of 30.233. This is 126.4% higher than average price of previous purchases of ARWR. |
| RNA - Avidity Biosciences Inc | BUY | 434 @ USD 71.86 | USD 31,187 | The ETF bought 434 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 71.86 compared to the previous average buy price of 47.0664. This is 52.7% higher than average price of previous purchases of RNA. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 224 @ USD 112.52 | USD 25,204 | The ETF bought 224 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 112.52 compared to the previous average buy price of 83.6905. This is 34.4% higher than average price of previous purchases of RYTM. |
| HALO - Halozyme Therapeutics Inc | BUY | 392 @ USD 63.45 | USD 24,872 | The ETF bought 392 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 63.45 compared to the previous average buy price of 61.6733. This is 2.9% higher than average price of previous purchases of HALO. |
| CYTK - Cytokinetics Inc | BUY | 400 @ USD 62.16 | USD 24,864 | The ETF bought 400 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 62.16 compared to the previous average buy price of 49.1459. This is 26.5% higher than average price of previous purchases of CYTK. |
| AXSM - Axsome Therapeutics Inc | BUY | 168 @ USD 146.24 | USD 24,568 | The ETF bought 168 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 146.24 compared to the previous average buy price of 123.822. This is 18.1% higher than average price of previous purchases of AXSM. |
| KRYS - Krystal Biotech Inc | BUY | 98 @ USD 242.98 | USD 23,812 | The ETF bought 98 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 242.98 compared to the previous average buy price of 177.565. This is 36.8% higher than average price of previous purchases of KRYS. |
| NUVL - Nuvalent Inc | BUY | 224 @ USD 104.97 | USD 23,513 | The ETF bought 224 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 104.97 compared to the previous average buy price of 88.8113. This is 18.2% higher than average price of previous purchases of NUVL. |
| KYMR - Kymera Therapeutics Inc | BUY | 240 @ USD 85.68 | USD 20,563 | The ETF bought 240 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 85.68 compared to the previous average buy price of 52.4555. This is 63.3% higher than average price of previous purchases of KYMR. |
| PTCT - PTC Therapeutics Inc | BUY | 268 @ USD 76.25 | USD 20,435 | The ETF bought 268 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 76.25 compared to the previous average buy price of 61.3713. This is 24.2% higher than average price of previous purchases of PTCT. |
| PTGX - Protagonist Therapeutics Inc | BUY | 210 @ USD 94.79 | USD 19,906 | The ETF bought 210 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 94.79 compared to the previous average buy price of 64.9151. This is 46.0% higher than average price of previous purchases of PTGX. |
| PCVX - Vaxcyte Inc | BUY | 438 @ USD 44.34 | USD 19,421 | The ETF bought 438 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 44.34 compared to the previous average buy price of 45.2743. This is -2.1% lower than average price of previous purchases of PCVX. |
| PRAX - Praxis Precision Medicines Inc | BUY | 70 @ USD 276.4 | USD 19,348 | The ETF bought 70 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 276.4 compared to the previous average buy price of 97.1383. This is 184.5% higher than average price of previous purchases of PRAX. |
| COGT - Cogent Biosciences Inc | BUY | 472 @ USD 40.24 | USD 18,993 | The ETF bought 472 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 40.24 compared to the previous average buy price of 19.3146. This is 108.3% higher than average price of previous purchases of COGT. |
| CRSP - Crispr Therapeutics AG | BUY | 306 @ USD 56.25 | USD 17,213 | The ETF bought 306 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 56.25 compared to the previous average buy price of 53.1732. This is 5.8% higher than average price of previous purchases of CRSP. |
| ADMA - ADMA Biologics Inc | BUY | 800 @ USD 19.73 | USD 15,784 | The ETF bought 800 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 19.73 compared to the previous average buy price of 17.7948. This is 10.9% higher than average price of previous purchases of ADMA. |
| ALKS - Alkermes Plc | BUY | 558 @ USD 28.17 | USD 15,719 | The ETF bought 558 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 28.17 compared to the previous average buy price of 30.0787. This is -6.3% lower than average price of previous purchases of ALKS. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 318 @ USD 49.32 | USD 15,684 | The ETF bought 318 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 49.32 compared to the previous average buy price of 38.0502. This is 29.6% higher than average price of previous purchases of CRNX. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 566 @ USD 27.26 | USD 15,429 | The ETF bought 566 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 27.26 compared to the previous average buy price of 22.0585. This is 23.6% higher than average price of previous purchases of ACAD. |
| IMVT - Immunovant Inc | BUY | 586 @ USD 26 | USD 15,236 | The ETF bought 586 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 26 compared to the previous average buy price of 19.1757. This is 35.6% higher than average price of previous purchases of IMVT. |
| SRRK - Scholar Rock Holding Corp | BUY | 322 @ USD 45.24 | USD 14,567 | The ETF bought 322 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 45.24 compared to the previous average buy price of 36.8348. This is 22.8% higher than average price of previous purchases of SRRK. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 1,056 @ USD 12.46 | USD 13,158 | The ETF bought 1056 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 12.46 compared to the previous average buy price of 9.65189. This is 29.1% higher than average price of previous purchases of AMRX. |
| TERN - Tern Plc | BUY | 296 @ USD 44.01 | USD 13,027 | The ETF bought 296 new shares of TERN (Tern Plc). The shares were bought for an average price of 44.01 compared to the previous average buy price of 11.5452. This is 281.2% higher than average price of previous purchases of TERN. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 200 @ USD 64.8 | USD 12,960 | The ETF bought 200 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 64.8 compared to the previous average buy price of 27.8264. This is 132.9% higher than average price of previous purchases of GPCR. |
| ACLX - Arcellx Inc | BUY | 188 @ USD 68.34 | USD 12,848 | The ETF bought 188 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 68.34 compared to the previous average buy price of 72.2701. This is -5.4% lower than average price of previous purchases of ACLX. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 66 @ USD 192.88 | USD 12,730 | The ETF bought 66 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 192.88 compared to the previous average buy price of 149.354. This is 29.1% higher than average price of previous purchases of LGND. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 156 @ USD 76.81 | USD 11,982 | The ETF bought 156 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 76.81 compared to the previous average buy price of 52.1489. This is 47.3% higher than average price of previous purchases of APGE. |
| RARE - Ultragenyx | BUY | 324 @ USD 36.23 | USD 11,739 | The ETF bought 324 new shares of RARE (Ultragenyx). The shares were bought for an average price of 36.23 compared to the previous average buy price of 35.9824. This is 0.7% higher than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 324 @ USD 36.23 | USD 11,739 | The ETF bought 324 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 36.23 compared to the previous average buy price of 35.9824. This is 0.7% higher than average price of previous purchases of RARE. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 404 @ USD 28.95 | USD 11,696 | The ETF bought 404 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 28.95 compared to the previous average buy price of 20.2275. This is 43.1% higher than average price of previous purchases of ARQT. |
| VCYT - Veracyte Inc | BUY | 264 @ USD 43.53 | USD 11,492 | The ETF bought 264 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 43.53 compared to the previous average buy price of 35.0769. This is 24.1% higher than average price of previous purchases of VCYT. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 142 @ USD 80.48 | USD 11,428 | The ETF bought 142 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 80.48 compared to the previous average buy price of 56.8552. This is 41.6% higher than average price of previous purchases of TARS. |
| FOLD - Amicus Therapeutics Inc | BUY | 1,046 @ USD 10.88 | USD 11,380 | The ETF bought 1046 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 10.88 compared to the previous average buy price of 8.10738. This is 34.2% higher than average price of previous purchases of FOLD. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 258 @ USD 43.6 | USD 11,249 | The ETF bought 258 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 43.6 compared to the previous average buy price of 37.6845. This is 15.7% higher than average price of previous purchases of XENE. |
| GRAL - GRAIL, LLC | BUY | 120 @ USD 91.04 | USD 10,925 | The ETF bought 120 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 91.04 compared to the previous average buy price of 64.4049. This is 41.4% higher than average price of previous purchases of GRAL. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 168 @ USD 64.1 | USD 10,769 | The ETF bought 168 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 64.1 compared to the previous average buy price of 59.5252. This is 7.7% higher than average price of previous purchases of MIRM. |
| IRON - Ironveld Plc | BUY | 116 @ USD 92 | USD 10,672 | The ETF bought 116 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 92 compared to the previous average buy price of 66.1823. This is 39.0% higher than average price of previous purchases of IRON. |
| VERA - Vera Therapeutics Inc | BUY | 216 @ USD 49.21 | USD 10,629 | The ETF bought 216 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 49.21 compared to the previous average buy price of 30.2877. This is 62.5% higher than average price of previous purchases of VERA. |
| TVTX - Travere Therapeutics Inc | BUY | 302 @ USD 34.76 | USD 10,498 | The ETF bought 302 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 34.76 compared to the previous average buy price of 24.2932. This is 43.1% higher than average price of previous purchases of TVTX. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 424 @ USD 24.56 | USD 10,413 | The ETF bought 424 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 24.56 compared to the previous average buy price of 21.1423. This is 16.2% higher than average price of previous purchases of APLS. |
| CGON - CG Oncology, Inc. Common stock | BUY | 256 @ USD 39.75 | USD 10,176 | The ETF bought 256 new shares of CGON (CG Oncology, Inc. Common stock). The shares were bought for an average price of 39.75 compared to the previous average buy price of 33.1388. This is 20.0% higher than average price of previous purchases of CGON. |
| IDYA - Ideaya Biosciences Inc | BUY | 296 @ USD 33.37 | USD 9,878 | The ETF bought 296 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 33.37 compared to the previous average buy price of 26.2268. This is 27.2% higher than average price of previous purchases of IDYA. |
| DYN - Dyne Therapeutics Inc | BUY | 478 @ USD 19.59 | USD 9,364 | The ETF bought 478 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 19.59 compared to the previous average buy price of 14.8561. This is 31.9% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 478 @ USD 19.59 | USD 9,364 | The ETF bought 478 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 19.59 compared to the previous average buy price of 14.8561. This is 31.9% higher than average price of previous purchases of DYN. |
| BEAM - Beam Therapeutics Inc | BUY | 344 @ USD 26.83 | USD 9,230 | The ETF bought 344 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 26.83 compared to the previous average buy price of 21.9369. This is 22.3% higher than average price of previous purchases of BEAM. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 188 @ USD 47.28 | USD 8,889 | The ETF bought 188 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 47.28 compared to the previous average buy price of 39.5619. This is 19.5% higher than average price of previous purchases of SUPN. |
| WVE - Wave Life Sciences Ltd | BUY | 542 @ USD 16.11 | USD 8,732 | The ETF bought 542 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 16.11 compared to the previous average buy price of 8.2641. This is 94.9% higher than average price of previous purchases of WVE. |
| DNLI - Denali Therapeutics Inc | BUY | 496 @ USD 17.34 | USD 8,601 | The ETF bought 496 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 17.34 compared to the previous average buy price of 16.2033. This is 7.0% higher than average price of previous purchases of DNLI. |
| EWTX - Edgewise Therapeutics Inc | BUY | 358 @ USD 23.94 | USD 8,571 | The ETF bought 358 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 23.94 compared to the previous average buy price of 17.994. This is 33.0% higher than average price of previous purchases of EWTX. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 326 @ USD 26.15 | USD 8,525 | The ETF bought 326 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 26.15 compared to the previous average buy price of 19.5564. This is 33.7% higher than average price of previous purchases of CNTA. |
| OCUL - Ocular Therapeutix Inc | BUY | 592 @ USD 14.17 | USD 8,389 | The ETF bought 592 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 14.17 compared to the previous average buy price of 10.5577. This is 34.2% higher than average price of previous purchases of OCUL. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 232 @ USD 35.83 | USD 8,313 | The ETF bought 232 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 35.83 compared to the previous average buy price of 11.1071. This is 222.6% higher than average price of previous purchases of OLMA. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 226 @ USD 36.02 | USD 8,141 | The ETF bought 226 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 36.02 compared to the previous average buy price of 24.6784. This is 46.0% higher than average price of previous purchases of MLYS. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 518 @ USD 15.69 | USD 8,127 | The ETF bought 518 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 15.69 compared to the previous average buy price of 13.4857. This is 16.3% higher than average price of previous purchases of ADPT. |
| HRMY - Harmony Biosciences Holdings | BUY | 196 @ USD 38.92 | USD 7,628 | The ETF bought 196 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 38.92 compared to the previous average buy price of 33.3588. This is 16.7% higher than average price of previous purchases of HRMY. |
| SRPT - Sarepta Therapeutics Inc | BUY | 334 @ USD 21.55 | USD 7,198 | The ETF bought 334 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 21.55 compared to the previous average buy price of 30.3513. This is -29.0% lower than average price of previous purchases of SRPT. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 452 @ USD 15.69 | USD 7,092 | The ETF bought 452 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 15.69 compared to the previous average buy price of 11.3772. This is 37.9% higher than average price of previous purchases of AUPH. |
| IBRX - Immunitybio Inc | BUY | 3,184 @ USD 2.22 | USD 7,068 | The ETF bought 3184 new shares of IBRX (Immunitybio Inc). The shares were bought for an average price of 2.22 compared to the previous average buy price of 2.63416. This is -15.7% lower than average price of previous purchases of IBRX. |
| AVDL - Avadel Pharmaceuticals PLC | BUY | 322 @ USD 21.42 | USD 6,897 | The ETF bought 322 new shares of AVDL (Avadel Pharmaceuticals PLC). The shares were bought for an average price of 21.42 compared to the previous average buy price of 13.7421. This is 55.9% higher than average price of previous purchases of AVDL. |
| SYRE - Spyre Therapeutics Inc. | BUY | 206 @ USD 33.34 | USD 6,868 | The ETF bought 206 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 33.34 compared to the previous average buy price of 21.6175. This is 54.2% higher than average price of previous purchases of SYRE. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 256 @ USD 25.97 | USD 6,648 | The ETF bought 256 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 25.97 compared to the previous average buy price of 17.3762. This is 49.5% higher than average price of previous purchases of ZYME. |
| TWST - Twist Bioscience Corp | BUY | 208 @ USD 31.07 | USD 6,463 | The ETF bought 208 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 31.07 compared to the previous average buy price of 34.6222. This is -10.3% lower than average price of previous purchases of TWST. |
| VCEL - Vericel Corp Ord | BUY | 174 @ USD 36.49 | USD 6,349 | The ETF bought 174 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 36.49 compared to the previous average buy price of 39.9104. This is -8.6% lower than average price of previous purchases of VCEL. |
| MNKD - MannKind Corp | BUY | 1,058 @ USD 5.94 | USD 6,285 | The ETF bought 1058 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.94 compared to the previous average buy price of 4.97212. This is 19.5% higher than average price of previous purchases of MNKD. |
| LEGN - Legend Biotech Corp | BUY | 282 @ USD 22.01 | USD 6,207 | The ETF bought 282 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 22.01 compared to the previous average buy price of 32.6554. This is -32.6% lower than average price of previous purchases of LEGN. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 296 @ USD 20.88 | USD 6,180 | The ETF bought 296 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 20.88 compared to the previous average buy price of 14.0989. This is 48.1% higher than average price of previous purchases of SNDX. |
| STOK - Stoke Therapeutics Inc | BUY | 186 @ USD 32.98 | USD 6,134 | The ETF bought 186 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 32.98 compared to the previous average buy price of 19.7182. This is 67.3% higher than average price of previous purchases of STOK. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 1,448 @ USD 4.2 | USD 6,082 | The ETF bought 1448 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 4.2 compared to the previous average buy price of 5.50853. This is -23.8% lower than average price of previous purchases of RXRX. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 146 @ USD 41.55 | USD 6,066 | The ETF bought 146 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 41.55 compared to the previous average buy price of 32.8331. This is 26.5% higher than average price of previous purchases of KNSA. |
| TXG - 10X Genomics Inc | BUY | 384 @ USD 15.76 | USD 6,052 | The ETF bought 384 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 15.76 compared to the previous average buy price of 13.5811. This is 16.0% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 384 @ USD 15.76 | USD 6,052 | The ETF bought 384 new shares of TXG (Terex Corporation). The shares were bought for an average price of 15.76 compared to the previous average buy price of 13.5811. This is 16.0% higher than average price of previous purchases of TXG. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 74 @ USD 81.51 | USD 6,032 | The ETF bought 74 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 81.51 compared to the previous average buy price of 75.7501. This is 7.6% higher than average price of previous purchases of ANIP. |
| HROW - Harrow Health Inc | BUY | 128 @ USD 45.7 | USD 5,850 | The ETF bought 128 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 45.7 compared to the previous average buy price of 37.1466. This is 23.0% higher than average price of previous purchases of HROW. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 726 @ USD 7.59 | USD 5,510 | The ETF bought 726 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 7.59 compared to the previous average buy price of 8.0371. This is -5.6% lower than average price of previous purchases of BCRX. |
| AGIO - Agios Pharm | BUY | 200 @ USD 26.85 | USD 5,370 | The ETF bought 200 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 26.85 compared to the previous average buy price of 33.8996. This is -20.8% lower than average price of previous purchases of AGIO. |
| TSHA - Taysha Gene Therapies Inc | BUY | 910 @ USD 5.76 | USD 5,242 | The ETF bought 910 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 5.76 compared to the previous average buy price of 3.26102. This is 76.6% higher than average price of previous purchases of TSHA. |
| COLL - Collegium Pharmaceutical Inc | BUY | 104 @ USD 49.01 | USD 5,097 | The ETF bought 104 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 49.01 compared to the previous average buy price of 35.644. This is 37.5% higher than average price of previous purchases of COLL. |
| NRIX - Nurix Therapeutics Inc | BUY | 268 @ USD 19.01 | USD 5,095 | The ETF bought 268 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 19.01 compared to the previous average buy price of 13.2022. This is 44.0% higher than average price of previous purchases of NRIX. |
| ARDX - Ardelyx Inc | BUY | 804 @ USD 6.2 | USD 4,985 | The ETF bought 804 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 6.2 compared to the previous average buy price of 4.92314. This is 25.9% higher than average price of previous purchases of ARDX. |
| IMCR - Immunocore Holdings Ltd | BUY | 136 @ USD 36.02 | USD 4,899 | The ETF bought 136 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 36.02 compared to the previous average buy price of 34.3138. This is 5.0% higher than average price of previous purchases of IMCR. |
| RLAY - Relay Therapeutics Inc | BUY | 576 @ USD 8.48 | USD 4,884 | The ETF bought 576 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 8.48 compared to the previous average buy price of 4.89949. This is 73.1% higher than average price of previous purchases of RLAY. |
| FTRE - Fortrea Holdings Inc. | BUY | 302 @ USD 16.06 | USD 4,850 | The ETF bought 302 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 16.06 compared to the previous average buy price of 8.43904. This is 90.3% higher than average price of previous purchases of FTRE. |
| NVCR - Novocure Ltd | BUY | 372 @ USD 12.97 | USD 4,825 | The ETF bought 372 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 12.97 compared to the previous average buy price of 15.4651. This is -16.1% lower than average price of previous purchases of NVCR. |
| SANA - Sana Biotechnology Inc | BUY | 878 @ USD 5.08 | USD 4,460 | The ETF bought 878 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 5.08 compared to the previous average buy price of 3.47264. This is 46.3% higher than average price of previous purchases of SANA. |
| GMAB - Genmab AS | BUY | 140 @ USD 31.57 | USD 4,420 | The ETF bought 140 new shares of GMAB (Genmab AS). The shares were bought for an average price of 31.57 compared to the previous average buy price of 25.5555. This is 23.5% higher than average price of previous purchases of GMAB. |
| INVA - Innoviva Inc | BUY | 218 @ USD 20.14 | USD 4,391 | The ETF bought 218 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 20.14 compared to the previous average buy price of 19.6403. This is 2.5% higher than average price of previous purchases of INVA. |
| DVAX - Dynavax Technologies Corporation | BUY | 392 @ USD 10.85 | USD 4,253 | The ETF bought 392 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 10.85 compared to the previous average buy price of 10.6268. This is 2.1% higher than average price of previous purchases of DVAX. |
| ANAB - AnaptysBio Inc | BUY | 92 @ USD 45.56 | USD 4,192 | The ETF bought 92 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 45.56 compared to the previous average buy price of 28.4337. This is 60.2% higher than average price of previous purchases of ANAB. |
| AMPH - Amphastar P | BUY | 154 @ USD 26.31 | USD 4,052 | The ETF bought 154 new shares of AMPH (Amphastar P). The shares were bought for an average price of 26.31 compared to the previous average buy price of 25.9382. This is 1.4% higher than average price of previous purchases of AMPH. |
| PCRX - Pacira BioSciences, Inc. | BUY | 150 @ USD 26.68 | USD 4,002 | The ETF bought 150 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 26.68 compared to the previous average buy price of 23.8882. This is 11.7% higher than average price of previous purchases of PCRX. |
| XNCR - Xencor Inc | BUY | 238 @ USD 16.79 | USD 3,996 | The ETF bought 238 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 16.79 compared to the previous average buy price of 12.5886. This is 33.4% higher than average price of previous purchases of XNCR. |
| XERS - Xeris Pharmaceuticals Inc | BUY | 558 @ USD 7.05 | USD 3,934 | The ETF bought 558 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 7.05 compared to the previous average buy price of 6.2445. This is 12.9% higher than average price of previous purchases of XERS. |
| PGEN - Precigen Inc | BUY | 1,022 @ USD 3.81 | USD 3,894 | The ETF bought 1022 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 3.81 compared to the previous average buy price of 2.71366. This is 40.4% higher than average price of previous purchases of PGEN. |
| SVRA - Savara Inc | BUY | 576 @ USD 6.61 | USD 3,807 | The ETF bought 576 new shares of SVRA (Savara Inc). The shares were bought for an average price of 6.61 compared to the previous average buy price of 3.71918. This is 77.7% higher than average price of previous purchases of SVRA. |
| QURE - Uniqure NV | BUY | 184 @ USD 20.43 | USD 3,759 | The ETF bought 184 new shares of QURE (Uniqure NV). The shares were bought for an average price of 20.43 compared to the previous average buy price of 23.6631. This is -13.7% lower than average price of previous purchases of QURE. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 298 @ USD 12.56 | USD 3,743 | The ETF bought 298 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 12.56 compared to the previous average buy price of 8.42051. This is 49.2% higher than average price of previous purchases of AMLX. |
| CSTL - Castle Biosciences Inc | BUY | 96 @ USD 38.88 | USD 3,732 | The ETF bought 96 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 38.88 compared to the previous average buy price of 26.3471. This is 47.6% higher than average price of previous purchases of CSTL. |
| SPRY - Silverback Therapeutics Inc | BUY | 348 @ USD 10.59 | USD 3,685 | The ETF bought 348 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 10.59 compared to the previous average buy price of 12.3218. This is -14.1% lower than average price of previous purchases of SPRY. |
| GRFS - Grifols SA ADR | BUY | 408 @ USD 9.02999 | USD 3,684 | The ETF bought 408 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 9.02999 compared to the previous average buy price of 9.17494. This is -1.6% lower than average price of previous purchases of GRFS. |
| URGN - UroGen Pharma Ltd | BUY | 160 @ USD 22.85 | USD 3,656 | The ETF bought 160 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 22.85 compared to the previous average buy price of 16.9564. This is 34.8% higher than average price of previous purchases of URGN. |
| NVAX - Novavax Inc | BUY | 544 @ USD 6.58 | USD 3,580 | The ETF bought 544 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 6.58 compared to the previous average buy price of 7.22432. This is -8.9% lower than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 544 @ USD 6.58 | USD 3,580 | The ETF bought 544 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 6.58 compared to the previous average buy price of 7.22432. This is -8.9% lower than average price of previous purchases of NVAX. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 242 @ USD 14.69 | USD 3,555 | The ETF bought 242 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 14.69 compared to the previous average buy price of 10.5588. This is 39.1% higher than average price of previous purchases of PHAT. |
| ABCL - Abcellera Biologics Inc | BUY | 1,004 @ USD 3.51 | USD 3,524 | The ETF bought 1004 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 3.51 compared to the previous average buy price of 3.82944. This is -8.3% lower than average price of previous purchases of ABCL. |
| ERAS - Erasca Inc | BUY | 1,020 @ USD 3.43 | USD 3,499 | The ETF bought 1020 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 3.43 compared to the previous average buy price of 2.02507. This is 69.4% higher than average price of previous purchases of ERAS. |
| ELVN - Enliven Therapeutics Inc. | BUY | 198 @ USD 17.17 | USD 3,400 | The ETF bought 198 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 17.17 compared to the previous average buy price of 20.9572. This is -18.1% lower than average price of previous purchases of ELVN. |
| TNGX - Tango Therapeutics Inc | BUY | 372 @ USD 9.12 | USD 3,393 | The ETF bought 372 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 9.12 compared to the previous average buy price of 7.28833. This is 25.1% higher than average price of previous purchases of TNGX. |
| NTLA - Intellia Therapeutics Inc | BUY | 364 @ USD 9.14 | USD 3,327 | The ETF bought 364 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 9.14 compared to the previous average buy price of 11.4726. This is -20.3% lower than average price of previous purchases of NTLA. |
| ABUS - Arbutus Biopharma Corp | BUY | 658 @ USD 4.95 | USD 3,257 | The ETF bought 658 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 4.95 compared to the previous average buy price of 3.84471. This is 28.7% higher than average price of previous purchases of ABUS. |
| KURA - Kura Oncology Inc | BUY | 304 @ USD 10.56 | USD 3,210 | The ETF bought 304 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 10.56 compared to the previous average buy price of 8.30995. This is 27.1% higher than average price of previous purchases of KURA. |
| ARVN - Arvinas Inc | BUY | 260 @ USD 12.34 | USD 3,208 | The ETF bought 260 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 12.34 compared to the previous average buy price of 9.95671. This is 23.9% higher than average price of previous purchases of ARVN. |
| MNMD - Mind Medicine Inc | BUY | 260 @ USD 12.08 | USD 3,141 | The ETF bought 260 new shares of MNMD (Mind Medicine Inc). The shares were bought for an average price of 12.08 compared to the previous average buy price of 9.52628. This is 26.8% higher than average price of previous purchases of MNMD. |
| VIR - Vir Biotechnology Inc | BUY | 464 @ USD 6.72 | USD 3,118 | The ETF bought 464 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 6.72 compared to the previous average buy price of 5.92953. This is 13.3% higher than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 464 @ USD 6.72 | USD 3,118 | The ETF bought 464 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 6.72 compared to the previous average buy price of 5.92953. This is 13.3% higher than average price of previous purchases of VIR. |
| KROS - Keros Therapeutics Inc | BUY | 144 @ USD 21.23 | USD 3,057 | The ETF bought 144 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 21.23 compared to the previous average buy price of 15.8327. This is 34.1% higher than average price of previous purchases of KROS. |
| JANX - Janux Therapeutics Inc | BUY | 202 @ USD 15.12 | USD 3,054 | The ETF bought 202 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 15.12 compared to the previous average buy price of 26.3658. This is -42.7% lower than average price of previous purchases of JANX. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 180 @ USD 16.9 | USD 3,042 | The ETF bought 180 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 16.9 compared to the previous average buy price of 13.5108. This is 25.1% higher than average price of previous purchases of KALV. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 326 @ USD 9.23001 | USD 3,009 | The ETF bought 326 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 9.23001 compared to the previous average buy price of 10.7279. This is -14.0% lower than average price of previous purchases of ORIC. |
| TBPH - Theravance Biopharma Inc | BUY | 168 @ USD 17.77 | USD 2,985 | The ETF bought 168 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 17.77 compared to the previous average buy price of 13.5661. This is 31.0% higher than average price of previous purchases of TBPH. |
| GERN - Geron Corporation | BUY | 2,134 @ USD 1.33 | USD 2,838 | The ETF bought 2134 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.33 compared to the previous average buy price of 1.44652. This is -8.1% lower than average price of previous purchases of GERN. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 342 @ USD 8.27 | USD 2,828 | The ETF bought 342 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 8.27 compared to the previous average buy price of 7.73285. This is 6.9% higher than average price of previous purchases of DAWN. |
| ZLAB - Zai Lab Ltd | BUY | 160 @ USD 17.34 | USD 2,774 | The ETF bought 160 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 17.34 compared to the previous average buy price of 31.0505. This is -44.2% lower than average price of previous purchases of ZLAB. |
| REPL - Replimune Group Inc | BUY | 270 @ USD 9.94999 | USD 2,686 | The ETF bought 270 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 9.94999 compared to the previous average buy price of 9.20707. This is 8.1% higher than average price of previous purchases of REPL. |
| PAHC - Phibro Animal Health Corporation | BUY | 66 @ USD 40.67 | USD 2,684 | The ETF bought 66 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 40.67 compared to the previous average buy price of 31.462. This is 29.3% higher than average price of previous purchases of PAHC. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 1,200 @ USD 2.16 | USD 2,592 | The ETF bought 1200 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 2.16 compared to the previous average buy price of 2.39505. This is -9.8% lower than average price of previous purchases of IOVA. |
| RGNX - Regenxbio Inc | BUY | 178 @ USD 13.83 | USD 2,462 | The ETF bought 178 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 13.83 compared to the previous average buy price of 10.0329. This is 37.8% higher than average price of previous purchases of RGNX. |
| MGTX - MeiraGTx Holdings PLC | BUY | 272 @ USD 8.90001 | USD 2,421 | The ETF bought 272 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 8.90001 compared to the previous average buy price of 7.4071. This is 20.2% higher than average price of previous purchases of MGTX. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 592 @ USD 4.04 | USD 2,392 | The ETF bought 592 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 4.04 compared to the previous average buy price of 3.87011. This is 4.4% higher than average price of previous purchases of PRME. |
| PACB - Pacific Biosciences of California | BUY | 1,078 @ USD 2.12 | USD 2,285 | The ETF bought 1078 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 2.12 compared to the previous average buy price of 1.72597. This is 22.8% higher than average price of previous purchases of PACB. |
| CGEM - Cullinan Oncology LLC | BUY | 206 @ USD 10.82 | USD 2,229 | The ETF bought 206 new shares of CGEM (Cullinan Oncology LLC). The shares were bought for an average price of 10.82 compared to the previous average buy price of 8.57342. This is 26.2% higher than average price of previous purchases of CGEM. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 592 @ USD 3.59 | USD 2,125 | The ETF bought 592 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 3.59 compared to the previous average buy price of 2.37058. This is 51.4% higher than average price of previous purchases of IRWD. |
| LYEL - Lyell Immunopharma Inc | BUY | 64 @ USD 32.4 | USD 2,074 | The ETF bought 64 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 32.4 compared to the previous average buy price of 6.98849. This is 363.6% higher than average price of previous purchases of LYEL. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 534 @ USD 3.67 | USD 1,960 | The ETF bought 534 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 3.67 compared to the previous average buy price of 2.93842. This is 24.9% higher than average price of previous purchases of MRVI. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 170 @ USD 10.95 | USD 1,861 | The ETF bought 170 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 10.95 compared to the previous average buy price of 7.81766. This is 40.1% higher than average price of previous purchases of FDMT. |
| PRTA - Prothena Corporation plc | BUY | 186 @ USD 9.97001 | USD 1,854 | The ETF bought 186 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 9.97001 compared to the previous average buy price of 9.51521. This is 4.8% higher than average price of previous purchases of PRTA. |
| EOLS - Evolus Inc | BUY | 240 @ USD 7.13999 | USD 1,714 | The ETF bought 240 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 7.13999 compared to the previous average buy price of 8.57331. This is -16.7% lower than average price of previous purchases of EOLS. |
| GLPG - Galapagos NV ADR | BUY | 52 @ USD 31.11 | USD 1,618 | The ETF bought 52 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 31.11 compared to the previous average buy price of 29.6619. This is 4.9% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 52 @ USD 31.11 | USD 1,618 | The ETF bought 52 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 31.11 compared to the previous average buy price of 29.6619. This is 4.9% higher than average price of previous purchases of GLPG. |
| LXRX - Lexicon Pharmaceuticals Inc | BUY | 1,300 @ USD 1.23 | USD 1,599 | The ETF bought 1300 new shares of LXRX (Lexicon Pharmaceuticals Inc). The shares were bought for an average price of 1.23 compared to the previous average buy price of 1.16152. This is 5.9% higher than average price of previous purchases of LXRX. |
| ALT - Altitude Group Plc | BUY | 294 @ USD 5.28001 | USD 1,552 | The ETF bought 294 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 5.28001 compared to the previous average buy price of 5.19923. This is 1.6% higher than average price of previous purchases of ALT. |
| TRDA - Entrada Therapeutics Inc | BUY | 140 @ USD 11.03 | USD 1,544 | The ETF bought 140 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 11.03 compared to the previous average buy price of 8.24308. This is 33.8% higher than average price of previous purchases of TRDA. |
| SIGA - SIGA Technologies Inc | BUY | 242 @ USD 6.32 | USD 1,529 | The ETF bought 242 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 6.32 compared to the previous average buy price of 6.63195. This is -4.7% lower than average price of previous purchases of SIGA. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 222 @ USD 6.62999 | USD 1,472 | The ETF bought 222 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 6.62999 compared to the previous average buy price of 4.91881. This is 34.8% higher than average price of previous purchases of VNDA. |
| HCM - HUTCHMED China Ltd | BUY | 110 @ USD 13.33 | USD 1,466 | The ETF bought 110 new shares of HCM (HUTCHMED China Ltd). The shares were bought for an average price of 13.33 compared to the previous average buy price of 15.1118. This is -11.8% lower than average price of previous purchases of HCM. |
| HCM - Hitachi Construction Machinery Co. Ltd | BUY | 110 @ USD 13.33 | USD 1,466 | The ETF bought 110 new shares of HCM (Hitachi Construction Machinery Co. Ltd). The shares were bought for an average price of 13.33 compared to the previous average buy price of 15.1118. This is -11.8% lower than average price of previous purchases of HCM. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 370 @ USD 3.41 | USD 1,262 | The ETF bought 370 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.41 compared to the previous average buy price of 4.6917. This is -27.3% lower than average price of previous purchases of RCKT. |
| AVXL - Anavex Life Sciences Corp | BUY | 298 @ USD 4.14 | USD 1,234 | The ETF bought 298 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 4.14 compared to the previous average buy price of 8.03679. This is -48.5% lower than average price of previous purchases of AVXL. |
| AUTL - Autolus Therapeutics Ltd | BUY | 756 @ USD 1.62 | USD 1,225 | The ETF bought 756 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.62 compared to the previous average buy price of 1.72772. This is -6.2% lower than average price of previous purchases of AUTL. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 162 @ USD 7.32999 | USD 1,187 | The ETF bought 162 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 7.32999 compared to the previous average buy price of 8.1605. This is -10.2% lower than average price of previous purchases of BCYC. |
| ACIU - AC Immune Ltd | BUY | 348 @ USD 3.23999 | USD 1,128 | The ETF bought 348 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 3.23999 compared to the previous average buy price of 2.57289. This is 25.9% higher than average price of previous purchases of ACIU. |
| ALLO - Allogene Therapeutics Inc | BUY | 762 @ USD 1.47 | USD 1,120 | The ETF bought 762 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.47 compared to the previous average buy price of 1.34844. This is 9.0% higher than average price of previous purchases of ALLO. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 290 @ USD 3.15 | USD 914 | The ETF bought 290 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 3.15 compared to the previous average buy price of 3.23954. This is -2.8% lower than average price of previous purchases of AVIR. |
| OABI - OmniAb Inc. | BUY | 430 @ USD 2.03 | USD 873 | The ETF bought 430 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 2.03 compared to the previous average buy price of 1.88299. This is 7.8% higher than average price of previous purchases of OABI. |
| EDIT - Editas Medicine Inc | BUY | 332 @ USD 2.44 | USD 810 | The ETF bought 332 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 2.44 compared to the previous average buy price of 2.61637. This is -6.7% lower than average price of previous purchases of EDIT. |
| VYGR - Voyager Therapeutics Inc | BUY | 178 @ USD 4.36 | USD 776 | The ETF bought 178 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 4.36 compared to the previous average buy price of 3.94316. This is 10.6% higher than average price of previous purchases of VYGR. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 98 @ USD 7.25001 | USD 711 | The ETF bought 98 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 7.25001 compared to the previous average buy price of 12.5538. This is -42.2% lower than average price of previous purchases of ARCT. |
| HUMA - Humacyte Inc | BUY | 566 @ USD 1.18 | USD 668 | The ETF bought 566 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 1.18 compared to the previous average buy price of 1.98779. This is -40.6% lower than average price of previous purchases of HUMA. |
| MXCT - MaxCyte Inc | BUY | 370 @ USD 1.49 | USD 551 | The ETF bought 370 new shares of MXCT (MaxCyte Inc). The shares were bought for an average price of 1.49 compared to the previous average buy price of 2.00261. This is -25.6% lower than average price of previous purchases of MXCT. |
| ALEC - Alector Inc | BUY | 368 @ USD 1.42001 | USD 523 | The ETF bought 368 new shares of ALEC (Alector Inc). The shares were bought for an average price of 1.42001 compared to the previous average buy price of 1.7128. This is -17.1% lower than average price of previous purchases of ALEC. |
| MRSN - Mersana Therapeutics Inc | BUY | 16 @ USD 28.5899 | USD 457 | The ETF bought 16 new shares of MRSN (Mersana Therapeutics Inc). The shares were bought for an average price of 28.5899 compared to the previous average buy price of 1.29528. This is 2,107.2% higher than average price of previous purchases of MRSN. |
| FATE - Fate Therapeutics Inc | BUY | 380 @ USD 1.12 | USD 426 | The ETF bought 380 new shares of FATE (Fate Therapeutics Inc). The shares were bought for an average price of 1.12 compared to the previous average buy price of 1.14857. This is -2.5% lower than average price of previous purchases of FATE. |
| BMEA - Biomea Fusion Inc | BUY | 240 @ USD 1.34 | USD 322 | The ETF bought 240 new shares of BMEA (Biomea Fusion Inc). The shares were bought for an average price of 1.34 compared to the previous average buy price of 1.51467. This is -11.5% lower than average price of previous purchases of BMEA. |
| MGNX - MacroGenics Inc | BUY | 214 @ USD 1.37 | USD 293 | The ETF bought 214 new shares of MGNX (MacroGenics Inc). The shares were bought for an average price of 1.37 compared to the previous average buy price of 1.53106. This is -10.5% lower than average price of previous purchases of MGNX. |
| STRO - Sutro Biopharma | BUY | 26 @ USD 9.92997 | USD 258 | The ETF bought 26 new shares of STRO (Sutro Biopharma). The shares were bought for an average price of 9.92997 compared to the previous average buy price of 1.02696. This is 866.9% higher than average price of previous purchases of STRO. |
| PLRX - Pliant Therapeutics Inc | BUY | 200 @ USD 1.24001 | USD 248 | The ETF bought 200 new shares of PLRX (Pliant Therapeutics Inc). The shares were bought for an average price of 1.24001 compared to the previous average buy price of 1.48485. This is -16.5% lower than average price of previous purchases of PLRX. |
| OKUR - OKUR | BUY | 42 @ USD 3.20004 | USD 134 | The ETF bought 42 new shares of OKUR (OKUR). The shares were bought for an average price of 3.20004 compared to the previous average buy price of 5.62636. This is -43.1% lower than average price of previous purchases of OKUR. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.04749. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-12-15 this would crystalise an overall loss. |